BACKGROUND: Dimethyl fumarate (DMF) is used to treat relapsing multiple sclerosis and causes lymphopenia in a subpopulation of treated individuals. Much remains to be learned about how the drug affects B- and T-lymphocytes. OBJECTIVES: To characterize changes in B- and T-cell phenotype and function induced by DMF and to investigate whether low absolute lymphocyte count (ALC) is associated with unique functional changes. METHODS: Peripheral blood mononuclear cells (PBMCs) were collected from DMF-treated patients, untreated patients, and healthy controls. A subset of DMF-treated patients was lymphopenic (ALC < 800). Multiparametric flow cytometry was used to evaluate cellular phenotypes. Functional response to non-specific and viral peptide stimulation was assessed. RESULTS: DMF reduced circulating memory B-cells regardless of ALC. Follicular T-helper cells (CD4+ CXCR5+) and mucosal invariant T-cells (CD8+ CD161+) were also reduced. DMF reduced T-cell production of pro-inflammatory cytokines in response to polyclonal (PMA/ionomycin) and viral peptide stimulation, regardless of ALC. No differences in activation-induced cell death or circulating progenitors were observed between lymphopenic and non-lymphopenic DMF-treated patients. CONCLUSION: These data implicate DMF-induced changes in lymphocytes as an important component of the drug's efficacy and expand our understanding of the functional significance of DMF-induced lymphopenia.
BACKGROUND:Dimethyl fumarate (DMF) is used to treat relapsing multiple sclerosis and causes lymphopenia in a subpopulation of treated individuals. Much remains to be learned about how the drug affects B- and T-lymphocytes. OBJECTIVES: To characterize changes in B- and T-cell phenotype and function induced by DMF and to investigate whether low absolute lymphocyte count (ALC) is associated with unique functional changes. METHODS: Peripheral blood mononuclear cells (PBMCs) were collected from DMF-treated patients, untreated patients, and healthy controls. A subset of DMF-treated patients was lymphopenic (ALC < 800). Multiparametric flow cytometry was used to evaluate cellular phenotypes. Functional response to non-specific and viral peptide stimulation was assessed. RESULTS:DMF reduced circulating memory B-cells regardless of ALC. Follicular T-helper cells (CD4+ CXCR5+) and mucosal invariant T-cells (CD8+ CD161+) were also reduced. DMF reduced T-cell production of pro-inflammatory cytokines in response to polyclonal (PMA/ionomycin) and viral peptide stimulation, regardless of ALC. No differences in activation-induced cell death or circulating progenitors were observed between lymphopenic and non-lymphopenic DMF-treatedpatients. CONCLUSION: These data implicate DMF-induced changes in lymphocytes as an important component of the drug's efficacy and expand our understanding of the functional significance of DMF-induced lymphopenia.
Authors: Christian Loeffler; Klaus Dietz; Ariane Schleich; Holger Schlaszus; Manuel Stoll; Richard Meyermann; Michel Mittelbronn Journal: Neuropathology Date: 2010-11-24 Impact factor: 1.906
Authors: Bob W van Oosten; Joep Killestein; Frederik Barkhof; Chris H Polman; Mike P Wattjes Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245
Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Martin Duddy; Masaaki Niino; Femina Adatia; Sherry Hebert; Mark Freedman; Harry Atkins; Ho Jin Kim; Amit Bar-Or Journal: J Immunol Date: 2007-05-15 Impact factor: 5.422
Authors: Sara A J Thompson; Joanne L Jones; Amanda L Cox; D Alastair S Compston; Alasdair J Coles Journal: J Clin Immunol Date: 2009-09-10 Impact factor: 8.317
Authors: Kamran Ghoreschi; Jürgen Brück; Christina Kellerer; Caishu Deng; Haiyan Peng; Oliver Rothfuss; Rehana Z Hussain; Anne R Gocke; Annedore Respa; Ivana Glocova; Nadejda Valtcheva; Eva Alexander; Susanne Feil; Robert Feil; Klaus Schulze-Osthoff; Rudolf A Rupec; Amy E Lovett-Racke; Ralf Dringen; Michael K Racke; Martin Röcken Journal: J Exp Med Date: 2011-10-10 Impact factor: 14.307
Authors: Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg Journal: PLoS One Date: 2013-03-01 Impact factor: 3.240
Authors: Robert J Fox; Andrew Chan; Ralf Gold; J Theodore Phillips; Krzysztof Selmaj; Ih Chang; Mark Novas; Jitesh Rana; Jing L Marantz Journal: Neurol Clin Pract Date: 2016-06
Authors: Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer Journal: Drug Saf Date: 2019-05 Impact factor: 5.606
Authors: Allison Lm Jordan; Jennifer Yang; Caitlyn J Fisher; Michael K Racke; Yang Mao-Draayer Journal: Mult Scler Date: 2020-08-18 Impact factor: 6.312